Drug Trial Radar · NCT05587712
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Jan 19, 2023
Primary completion
Sep 21, 2028
Study completion Sep 21, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.
Conditions
- Pulmonary Arterial Hypertension
Interventions
SotaterceptDrug
SC injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serum Trough Concentration (Ctrough) of SotaterceptTime frame: Predose Day 1, Day 21, Day 42, Day 63, Day 84, Day105, Day 126, Day 147, Day 168, Day 189. Postdose Day 7, Day 14, Day 64, Day 69 and Day 76
- Area Under the Curve at Steady State (AUCss) of SotaterceptTime frame: Predose Day 1, Day 21, Day 42, Day 63, Day 84, Day105, Day 126, Day 147, Day 168, Day 189. Postdose Day 7, Day 14, Day 64, Day 69 and Day 76
- Area Under the Curve from 0 to 3 weeks (AUC0-3 weeks) of SotaterceptTime frame: Predose Day 1, Day 7, Day 14, and Predose Day 21
- Percentage of Participants Who Experience at Least 1 Adverse Event (AE)Time frame: Up to 24 weeks
- Percentage of Participants Who Discontinue Study Drug Due to an AETime frame: Up to 24 weeks
- Laboratory Parameter (Hematology): Concentration of HemoglobinTime frame: Up to 24 weeks
- Laboratory Parameter (Hematology): HematocritTime frame: Up to 24 weeks
- Laboratory Parameter (Hematology): Red Blood Cell (RBC) CountTime frame: Up to 24 weeks
- Laboratory Parameter (Hematology): Reticulocyte CountTime frame: Up to 24 weeks
- Laboratory Parameter (Hematology): Platelet CountTime frame: Up to 24 weeks
- Blood Pressure (BP)Time frame: Up to 24 weeks
- Titer of Anti-drug Antibody (ADA) to SotaterceptTime frame: Up to 24 weeks
Locations
35 sites in 12 countries. Site status is shown where the registry gives one.
The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606)
Los Angeles, California · Recruiting
Stanford University School of Medicine ( Site 1603)
Palo Alto, California · Recruiting
UCSF Benioff Children's Hospital San Francisco ( Site 1611)
San Francisco, California · Recruiting
Children's Hospital Colorado ( Site 1609)
Aurora, Colorado · Recruiting
Children's National Medical Center ( Site 1600)
Washington D.C., District of Columbia · Recruiting
Cincinnati Children's Hospital Medical Center ( Site 1602)
Cincinnati, Ohio · Recruiting
Children's Hospital of Philadelphia (CHOP) ( Site 1608)
Philadelphia, Pennsylvania · Recruiting
Monroe Carell Jr. Children's Hospital ( Site 1601)
Nashville, Tennessee · Completed
Seattle Children's Hospital ( Site 1605)
Seattle, Washington · Recruiting
Children's Wisconsin ( Site 1610)
Milwaukee, Wisconsin · Recruiting
The Children's Hospital at Westmead ( Site 0001)
Westmead, New South Wales, Australia · Recruiting
Clinica Somer-Unidad de Investigacion y Docencia ( Site 0205)
Rionegro, Antioquia, Colombia · Recruiting
Fundación Valle del Lili ( Site 0200)
Cali, Valle del Cauca Department, Colombia · Recruiting
Clínica Imbanaco S.A.S ( Site 0203)
Cali, Valle del Cauca Department, Colombia · Recruiting
Hôpital Universitaire Necker Enfants Malades ( Site 0300)
Paris, France · Recruiting
CHU de Toulouse - Hôpital des Enfants ( Site 0302)
Toulouse, Haute-Garonne, France · Recruiting
Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone ( Site 0303)
Marseille, Provence-Alpes-Côte d'Azur Region, France · Recruiting
Universitaetsklinikum Heidelberg ( Site 0401)
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
Klinikum der Universität München Großhadern ( Site 0404)
München, Bavaria, Germany · Recruiting
Medizinische Hochschule Hannover ( Site 0405)
Hanover, Lower Saxony, Germany · Recruiting
Schneider Children's Medical Center ( Site 0603)
Petah Tikva, Israel · Recruiting
Sheba Medical Center ( Site 0601)
Ramat Gan, Israel · Recruiting
University Medical Center Groningen ( Site 0900)
Groningen, Netherlands · Recruiting
Centrum Zdrowia Dziecka w Warszawie-Klinika Kardiologii ( Site 1103)
Warsaw, Masovian Voivodeship, Poland · Recruiting
Uniwersyteckie Centrum Kliniczne-Klinika Kardiologii Dziecięcej i Wad Wrodzonych Serca ( Site 1102)
Gdansk, Pomeranian Voivodeship, Poland · Recruiting
Wits Clinical Research-Chris Hani Baragwanath Hospital ( Site 1201)
Johannesburg, Soweto, Gauteng, South Africa · Recruiting
Hospital Universitari Vall d'Hebron ( Site 1302)
Barcelona, Spain · Recruiting
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 1301)
Madrid, Spain · Recruiting
Hospital Universitario Ramón y Cajal ( Site 1300)
Madrid, Madrid, Comunidad de, Spain · Recruiting
Hospital Universitari i Politecnic La Fe ( Site 1303)
Valencia, Valencia, Spain · Recruiting
Hacettepe Universite Hastaneleri ( Site 1400)
Ankara, Turkey (Türkiye) · Recruiting
Gazi University Health Research and Application Center Gazi -Çocuk Sağlığı ve Hastalıkları Anabilim ( Site 1402)
Ankara, Turkey (Türkiye) · Recruiting
Ankara Bilkent Şehir Hastanesi. ( Site 1403)
Ankara, Turkey (Türkiye) · Recruiting
Mehmet Akif Ersoy Research and Training Hospital ( Site 1404)
Istanbul, Turkey (Türkiye) · Recruiting
Great Ormond Street Hospital For Children NHS Foundation Trust ( Site 1500)
London, London, City of, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.